Chemotherapy for Stage 4 Lung Cancer: 217 Real Stories

Stage IV lung cancer presenting with a paraneoplastic neurologic syndrome and mixed tumor features

Patient Info: Anonymized, Male, 40s | Stage IV

Biomarkers: PD-L1 0%

Metastatic Site: bone (T10 and L5 vertebrae)

He died after rapid deterioration with severe encephalopathy, weakness and respiratory distress; advanced metastatic lung cancer with progressive paraneoplastic neurologic involvement was considered the most likely cause.

PubMed CentralRead more →

Stage IVA EGFR-mutant lung adenocarcinoma: clonal evolution, chemoimmunotherapy response, osimertinib rechallenge, and death after progression

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: Markers changed over time: started with EGFR L747S/L858R; later MET-amplified, PD-L1 TPS 80%, high TMB clone; later EGFR reappeared.

Metastatic Site: pleura, peritoneal nodule, retroperitoneal lymph nodes

The patient died on 30 April 2025 after progression through multiple lines and infection related to treatment-associated myelosuppression.

PubMed CentralRead more →

Stage IV EGFR Lung Cancer: Shannon's Survivor Story

Patient Info: Shannon, Female, Under 40 | Stage IV

Biomarkers: EGFR mutation; TP53 mutation

Metastatic Site: cervical spine (C1/C2 and C4/C6), liver

As of June 2026, Shannon described no evidence of active disease: visible tumors were gone, the original lung mass had decreased from 10.8 cm to a 3.8 cm cavity, and targeted therapy continued to suppress possible remaining cells.

The Patient StoryRead more →

Stage IV PD-L1-high lung adenocarcinoma: remission on chemotherapy after tislelizumab-associated KLHL11-IgG cerebellitis

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: PD-L1-high lung adenocarcinoma with EGFR/ALK/ROS1 wild type and TTF-1 positive. KLHL11-IgG was linked to cerebellitis.

Metastatic Site: M1a disease; specific metastatic site not otherwise…

At 1-year neurologic follow-up, the cerebellitis had markedly improved, serum KLHL11-IgG was negative, brain MRI lesions had resolved, and lung adenocarcinoma remained in remission on cisplatin plus pemetrexed.

PubMed CentralRead more →

Stage IV EGFR-mutated lung adenocarcinoma: high-dose furmonertinib after CNS progression

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Initial EGFR L858R mutation. Later blood testing showed EGFR p.S553Y variation; CEA rose and fell with treatment.

Metastatic Site: brain/meninges; bilateral pleura/lungs; mediastinal…

As of June-September 2024, the left lung lesion was stable to slightly smaller on escalated furmonertinib, but brain/CNS lesions had progressed and required dose escalation to 240 mg/day; later imaging was declined.

PubMed CentralRead more →

Stage IV Non-Small Cell Lung Cancer: Jill's Patient Story

Patient Info: Jill, Female, 50s | Stage IV

Biomarkers: Driver mutation identified; specific mutation not stated

Metastatic Site: pleura

As of May 2026, Jill had lived 17 years with NSCLC, later experienced pleural metastases/progression, and remained on biomarker-guided targeted therapy with chemotherapy added.

The Patient StoryRead more →

Stage IV EGFR-mutated lung cancer responds after targeted therapy intolerance

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: EGFR L858R mutation; PIK3CA E545K mutation; acquired ROS1 rearrangement

Metastatic Site: pleura|pericardium|bone|lungs

Chemotherapy produced a partial response that remained sustained for 7 months at the latest follow-up.

PubMed CentralRead more →

Stage IV ALK Lung Cancer: Jake's Patient Story

Patient Info: Jake, Male, Under 40 | Stage IV

Biomarkers: ALK-positive mutation

Metastatic Site: brain; lung; ankle bone

As of May 2026, Jake was 28 and had lived more than 13 years with Stage IV ALK-positive lung cancer, with ongoing treatment history including targeted therapy, surgeries, radiation, clinical-trial therapy, and recent chemotherapy.

The Patient StoryRead more →

More than 5 years of disease control with maintenance chemotherapy for Stage IV lung cancer

Patient Info: Anonymized, Male | Stage IV

Biomarkers: KRAS mutation; TP53 mutation

Metastatic Site: brain

After more than 60 months of follow-up and prolonged maintenance chemotherapy, the latest assessment found no evidence of current tumor progression.

PubMed CentralRead more →

Stage IV squamous NSCLC: durable pembrolizumab response followed by invasive aspergillosis, marrow failure, and death

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: PD-L1 20%

Metastatic Site: bilateral lungs

After durable partial response to pembrolizumab-based therapy, he developed severe pulmonary infection, invasive pulmonary aspergillosis, progressive AA-like bone marrow failure with severe cytopenias, declined further treatment, and died at home in early 2025.

PubMed CentralRead more →

Stage IV squamous lung cancer with steroid-refractory immune-related gastritis after pembrolizumab

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: Gastric biopsy during immune gastritis showed CD8-positive lymphocyte inflammation, no cancer

After about 2 years of carboplatin, pemetrexed, and pembrolizumab, lung cancer treatment was stopped because of tumor growth; the later immune-related gastritis improved after escalation to infliximab, while the cancer course remained a setback/progression story.

PubMed CentralRead more →

Stage IV lung cancer response followed by immune-related lung inflammation

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: EGFR-negative; ALK-negative; ROS1-negative

Metastatic Site: pleura

After the lung inflammation improved, he did not resume tumor-directed chemotherapy, immunotherapy, or radiation and remained generally well.

PubMed CentralRead more →

Stage IV EGFR Lung Cancer: Kelsey's Patient Story

Patient Info: Kelsey, Female, Under 40 | Stage IV

Biomarkers: EGFR mutation; later ALK mutation after progression

Metastatic Site: Bone — pelvis and spine/L5

Living with Stage IV lung cancer on a clinical trial after progression, with current treatment described as working and quality of life improved.

The Patient StoryRead more →

Stage IV Non-Small Cell Lung Cancer: Natalie's Patient Story

Patient Info: Natalie, Female, Under 40 | Stage IV

Metastatic Site: Spine

Natalie was living with Stage IV NSCLC after a double lung transplant gave her new lung function, but cancer later appeared in the spine and required renewed chemotherapy and radiation.

The Patient StoryRead more →

Stage IV EGFR-positive lung cancer treated for nearly 5 years before progression

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: EGFR L858R mutation

Metastatic Site: liver

The cancer later progressed despite chemotherapy, and he died from lung cancer 4 years and 8 months after diagnosis.

PubMed CentralRead more →

Stage IV EGFR Non-Small Cell Lung Cancer: Maggie's Patient Story

Patient Info: Maggie, Female, 60s | Stage IV

Biomarkers: EGFR mutation; MET amplification resistance mutation; MET overexpression

Metastatic Site: Brain

Maggie initially reached no evidence of disease on EGFR-targeted therapy, but later had repeated progression, including MET-amplification resistance and MET overexpression, requiring SBRT, a clinical trial, chemotherapy, and later-line targeted treatment.

The Patient StoryRead more →

Stage IV ALK Non-Small Cell Lung Cancer: Clara's Patient Story

Patient Info: Clara, Female, Under 40 | Stage IV

Biomarkers: ALK-positive / ALK-rearranged after repeat Tempus testing

Metastatic Site: Pelvis; spleen

As of February 2026, ALK-targeted therapy had improved Clara’s symptoms enough that she no longer needed a walker or cane, and upcoming scans would determine whether pelvic tumor surgery remained an option.

The Patient StoryRead more →

Stage IVB lung adenocarcinoma with severe immune-related complications

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: PD-L1 TPS 20%; BRAF mutation

Metastatic Site: left supraclavicular fossa, left axilla, right hilum,…

The patient had an initial partial response to ipilimumab/nivolumab but developed severe immune-related pneumonitis, thrombocytopenia, and aplastic anemia. Cytopenias recovered with eltrombopag, but lung cancer later relapsed with carcinomatous meningitis, and he died 20 months after diagnosis.

PubMed CentralRead more →

Stage IV ROS1 Lung Cancer: Phil's Patient Story

Patient Info: Phil, Male, 60s | Stage IV

Biomarkers: ROS1 mutation

Metastatic Site: Lymph nodes; other lung

Phil was living with incurable Stage IV ROS1-positive lung cancer. After initial chemotherapy, a ROS1-targeted pill worked for about 2 years, and he later continued on a Mass General clinical-trial treatment with follow-up every 3 months.

The Patient StoryRead more →

Stage IV ALK Non-Small Cell Lung Cancer: Stephanie's Patient Story

Patient Info: Stephanie, Female, 40s | Stage IV

Biomarkers: ALK mutation / ALK-positive

Metastatic Site: ovaries; spine; liver; lung

Stage IV ALK-positive NSCLC is being managed with ALK-directed treatment; follow-up scans were described as improving, but the source does not state complete remission.

The Patient StoryRead more →

Stage 4 lung cancer: large tumor managed with targeted care

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: PD-L1 TPS <1%

Metastatic Site: contralateral lymph nodes, supraclavicular lymph…

The patient had a partial response to CheckMate 9LA despite PD-L1 TPS <1%, later progressed after 24 cycles of immunotherapy, received additional chemotherapy, and died in November 20XX+2.

PubMed CentralRead more →

EGFR-mutant lung adenocarcinoma with acquired ROS1 rearrangement after EGFR-TKI resistance

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: EGFR exon 19 deletion; acquired EGFR T790M; acquired EZR exon10-ROS1 exon34 rearrangement

Metastatic Site: bone (distal femur); contralateral lung;…

After fourth-line crizotinib for acquired EZR-ROS1 rearrangement, response evaluation on August 27, 2025 showed partial response, and September 2025 bone scan showed stable bone lesions.

PubMed CentralRead more →

Stage 4 lung cancer: persistent cough led to diagnosis

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: KRAS and TP53 ; PD-L1 TPS 95%. Other common lung drivers were not detected.

Metastatic Site: liver, left adrenal gland, lymph nodes, pleural…

After more than 2 years of disease control and partial response on antiangiogenic therapy plus sintilimab, the patient developed fulminant immune-checkpoint-inhibitor-induced type 1 diabetes with severe diabetic ketoacidosis, inflammatory crisis, sepsis, and died shortly after discharge against medical advice.

PubMed CentralRead more →

EGFR-Mutant Lung Adenocarcinoma With Bone and Leptomeningeal Metastases

Patient Info: Anonymized, male, 40s | Stage IV

Biomarkers: EGFR exon 19 deletion; acquired EGFR T790M mutation

Metastatic Site: bone, leptomeninges

In May 2025, leptomeningeal disease remained present and he continued combination chemotherapy with bevacizumab and high-dose furmonertinib, leaving hospital in stable condition after cycle 8.

PubMed CentralRead more →